SciSparc Ltd.
SPRCHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeSciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. With a market capitalization of $25.1M, it sits in micro-cap territory. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.
Market Cap
$25.1M
Beta
2.55
P/E (TTM)
0.00
P/E (Fwd)
—
EPS (TTM)
$248.24
EPS (Fwd)
—
ROE
-164.5%
ROA
-26.1%
Cash
$4.4M
Total Debt
$2.7M
Free CF
-$343,250
52W Change
-97.0%
Annual Financials
Cash vs Debt
Where SPRC stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, SPRC finished 75.52% below its 150-day moving average ($5.72) and 77.09% below its 200-day moving average ($6.11). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SPRC overbought or oversold?
At the October 20, 2026 close, SPRC's RSI(14) was 12.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
SciSparc Ltd. holds $4.4M in cash against $2.7M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$343K. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -164.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $1.3M (2022) to $856K (2025), a 36% decline worth watching.
SciSparc Ltd.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing SPRC's risk profile alongside its fundamentals and technical indicators provides a more complete picture.